Eventide Gilead Fund
Eventide Healthcare & Life Sciences Fund
Eventide Multi-Asset Income Fund
Eventide Global Dividend Opportunities Fund
Eventide Limited-Term Bond Fund
Forms & Literature
Menu Invest With Us My Account
Eventide Gilead Fund and Eventide Healthcare & Life Sciences Fund Named WSJ Category Kings
Boston, MA – The Eventide Gilead Fund and the Eventide Healthcare & Life Sciences Fund were both named as "Category Kings" by The Wall Street Journalfor the one-year period ending March 31, 2019. The Category King award recognizes the top 10 performing funds in each equity category for trailing one-year total return. The Eventide Gilead Fund (NASDAQ: ETILX) ranked #4 in the Midcap Growth category out of 401 funds, and the Eventide Healthcare & Life Sciences Fund (NASDAQ: ETIHX) ranked #1 in the Health & Biotech category out of 97 funds.
The Eventide Funds are guided by an approach that seeks to deliver market outperformance to investors by investing in companies whose products and practices help create a better world. Eventide CIO Finny Kuruvilla, MD, PhD, commented on the approach: "Investing, for all its seeming sophistication, is simply the act of owning companies. What sets Eventide investors apart is a desire to invest in companies that are serving society and human flourishing. It is so gratifying to be able to work on behalf of those who want their use of money to follow and express their values and commitments."
The Eventide Funds are managed by Eventide Asset Management, a Boston-based registered investment adviser practicing investing that makes the world rejoice.®
Registration of an investment adviser does not imply a certain level of skill or training.
This press release isnot intended to constitute investment advice. Rather, you should use the rankings for informational purposes only. Rankings are only one form of performance measurement. Past performance is no guarantee of future results.
The Wall Street JournalCategory King is awarded to the top 10 funds in their Lipper Category based on trailing one-year total return absolute rank. The award does not account for sales loads, where applicable. Where a Fund offers multiple share classes, the award is designated for the largest share class by assets under management.
The Funds offers other share classes for which rankings may differ based on fees: other share classes for the Eventide Gilead Fund are NASDAQ: ETGLX, NASDAQ: ETAGX, NASDAQ: ETCGX and other share classes for the Eventide Healthcare & Life Sciences Fund are NASDAQ: ETNHX, NASDAQ: ETAHX, and NASDAQ: ETCHX.
The above expresses the views of Eventide Asset Management, LLC, and there is no guarantee that such views are accurate. Eventide's approach may not produce the desired results.
Eventide uses its trademark ("Investing that makes the world rejoice®") in a figurative manner to help explain its focus on serving investors by helping to improve the world.
Mutual Funds involve risk including the possible loss of principal. Past performance does not guarantee future results.
The Funds' ethical values screening criteria could cause it to under-perform similar funds that do not have such screening criteria. The Funds can have risk related to option investing. There are special risks associated with investments in foreign companies including exposure to currency fluctuations, less efficient trading markets, political instability and differing auditing and legal standards.
The Eventide Gilead Fund & Eventide Healthcare & Life Sciences Fund can invest in smaller-sized companies which may experience higher failure rates than larger companies and they normally have a lower trading volume than larger companies. The Funds can also have risk associated with the biotechnology and pharmaceutical industry in which these companies may be heavily dependent on clinical trials with uncertain outcomes and decisions made by the U.S. Food and Drug Administration. The Funds can invest in private companies. Private investments include various risks including but not limited to lack of liquidity, capital commitment risk, and valuation risk. Private companies may not be financially profitable and have uncertain futures, subjecting them to additional risks. Investors in the Gilead Fund should be aware that companies in the technology industries have different risks including but not limited to products becoming obsolete, and entrance of competing products. Companies in the Industrial Sector also carry various risks including, but not limited to, risk related to debt loads and intense competition.
An investor should consider the Funds' investment objectives, risks, charges and expenses carefully before investing or sending money. This and other important information can be found in the prospectus, which can be obtained at www.eventidefunds.com or by calling 1-877-771-EVEN (3836). Please read the prospectus carefully before investing. Eventide mutual funds are distributed by Northern Lights Distributors, LLC, Member FINRA/SIPC, which is not affiliated with Eventide Asset Management, LLC.
Fund contact:
Jason Myhre
877-771-EVEN (3836), x56
News › Eventide Gilead Fund and Eventide Healthcare & Life Sciences Fund Named WSJ Category Kings
Mutual Funds involve risk including the possible loss of principal. Past performance does not guarantee future results. The Funds' ethical values screening criteria could cause it to under-perform similar funds that do not have such screening criteria. The Funds can have risk related to option investing. There are special risks associated with investments in foreign companies including exposure to currency fluctuations, less efficient trading markets, political instability and differing auditing and legal standards.
The Eventide Gilead Fund and Eventide Healthcare & Life Sciences Fund can invest in smaller-sized companies which may experience higher failure rates than larger companies and they normally have a lower trading volume than larger companies. The Funds can also have risk associated with the biotechnology and pharmaceutical industry in which these companies may be heavily dependent on clinical trials with uncertain outcomes and decisions made by the U.S. Food and Drug Administration. The Funds can invest in private companies. Private investments include various risks including but not limited to lack of liquidity, capital commitment risk, and valuation risk. Private companies may not be financially profitable and have uncertain futures, subjecting them to additional risks. Investors in the Gilead Fund should be aware that companies in the technology industries have different risks including but not limited to products becoming obsolete, and entrance of competing products.
Investors in the Eventide Multi-Asset Income Fund should be aware that interest rates are at historic lows and may change at any time based on government policy. In general, the price of a fixed income security falls when interest rates rise. A rise in interest rates may result in volatility and increased redemptions, which in turn could result in the fund being forced to liquidate portfolio securities at disadvantageous prices. Longer- term securities may be more sensitive to changes in interest rates. The intermediate-term bond portion of the Multi-Asset Income Fund's portfolio may represent 0% to 100% of the Fund's portfolio with an average duration of between two and eight years. The Eventide Multi-Asset Income Fund may invest in other funds. If other funds are utilized, such underlying funds are subject to investment advisory and other expenses, which will be indirectly paid by the Fund. As a result, your cost of investing in the Fund will be higher than the cost of investing directly in underlying funds and may be higher than other mutual funds that do not invest in underlying funds. The Fund may invest, directly or indirectly, in "junk bonds." Such securities are speculative investments that carry greater risks than higher quality debt securities. There are unique risks associated with REITs, preferred stocks, convertible bonds, and BDCs that are covered in the Fund's prospectus and SAI.
The Eventide Multi-Asset Income Fund and Eventide Global Dividend Opportunities Fund can invest in MLPs and Yieldcos. MLPs carry unique risks including risks surrounding its tax status and risk pertaining to rising interest rates, both of which can negatively impact share price. Yieldcos carry different risks including Yieldco Sponsor Risk and cash flow risk. The Eventide Global Dividend Opportunities Fund can invest in Industrials and Utilities. Companies in the Industrial Sector carry various risks including, but not limited to, risk related to debt loads, intense competition, and sensitivity to economic cycles. Companies in the Utilities sector are subject to interest rate risk and cash flow risk. The Eventide Global Dividend Opportunities Fund is a new mutual fund and has a limited history of operations for investors to evaluate.
An investor should consider a fund's investment objectives, risks, charges and expenses carefully before investing or sending money. This and other important information can be found in the prospectus, which can be obtained at www.eventidefunds.com or by calling 1-877-771-EVEN (3836). Please read the prospectus carefully before investing. Eventide Mutual Funds are distributed by Northern Lights Distributors, LLC, Member FINRA, which is not affiliated with Eventide Asset Management, LLC.
4595-NLD-4/16/2019
877-771-EVEN (3836)
Eventide Asset Management, LLC
One International Place, Suite #4210
Eventide Funds
c/o Gemini Fund Services, LLC
17605 Wright Street
Connect With Eventide